Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy: insights from a clinical case series

Abstract

Cerebral amyloid angiopathy (CAA) is a small vessel disease characterized by the deposition of amyloid-beta in small cerebral vessels, which can lead to intracerebral hemorrhages and cognitive impairment. Rare variants, such as cerebral amyloid angiopathy-related inflammation (CAA-ri) and iatrogenic CAA (ICAA), may mimic other neurological conditions and challenge diagnosis in clinical practice. We present three cases that illustrate distinct CAA syndromes, along with CSF biomarker analysis. One patient experienced recurrent hemorrhagic strokes with a history of dural graft, raising concerns about amyloid transmission. Two patients presented with rapidly progressive dementia that fulfilled CAA-ri criteria. All cases exhibited decreased levels of CSF Aβ40 and Aβ42, with one showing elevated p-tau, suggesting comorbid Alzheimer's pathology. Cerebrospinal fluid biomarkers complement neuroimaging in the diagnosis of CAA, aiding in differentiation from other dementias. Early recognition and diagnosis of CAA-ri variants is crucial, because immunotherapy may improve outcomes. Further research is necessary to establish biomarker thresholds and their clinical applicability.

Keywords

Cerebral Amyloid Angiopathy - Biomarkers - Amyloid Beta-Peptides - Cerebrospinal Fluid

• References

• 1 Zedde M, Piazza F, Pascarella R. Clinical and Neuroradiological Manifestations of Cerebral Amyloid Angiopathy: A Closer Look into the Natural History of a Frequent Disease. J Clin Med 2025; 14 (05) 1697
• 2 Auriel E, Charidimou A, Gurol ME. et al. Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation. JAMA Neurol 2016; 73 (02) 197-202
• 3 Antolini L, DiFrancesco JC, Zedde M. et al. Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study. Neurology 2021; 97 (18) e1809-e1822
• 4 Charidimou A, Boulouis G. Core CSF Biomarker Profile in Cerebral Amyloid Angiopathy: Updated Meta-Analysis. Neurology 2024; 103 (07) e209795
• 5 Banerjee G, Samra K, Adams ME. et al. Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon. J Neurol Neurosurg Psychiatry 2022; -jnnp-2022-328792
• 6 Charidimou A, Boulouis G, Frosch MP. et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol 2022; 21 (08) 714-725
• 7 Jäkel L, De Kort AM, Klijn CJM, Schreuder FHBM, Verbeek MM. Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. Alzheimers Dement 2022; 18 (01) 10-28
• 8 Singh B, Lavezo J, Gavito-Higueroa J. et al. Updated Outlook of Cerebral Amyloid Angiopathy and Inflammatory Subtypes: Pathophysiology, Clinical Manifestations, Diagnosis and Management. J Alzheimers Dis Rep 2022; 6 (01) 627-639
• 9 Piazza F, Greenberg SM, Savoiardo M. et al. Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol 2013; 73 (04) 449-458
• 10 Sembill JA, Lusse C, Linnerbauer M. et al. Cerebrospinal fluid biomarkers for cerebral amyloid angiopathy. Brain Commun 2023; 5 (03) fcad159
• 11 Kaushik K, van Etten ES, Siegerink B. et al. Iatrogenic Cerebral Amyloid Angiopathy Post Neurosurgery: Frequency, Clinical Profile, Radiological Features, and Outcome. Stroke 2023; 54 (05) 1214-1223
• 12 De Kort AM, Kuiperij HB, Marques TM. et al. Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy. Ann Neurol 2023; 93 (06) 1173-1186